Dr. Ulahannan on the PRODIGE Trial in Pancreatic Cancer
Susanna Ulahannan, MD, assistant professor, Section of Hematology/Oncology, associate director, Oklahoma TSET Phase I Program, Stephenson Cancer Center, The University of Oklahoma, discusses the PRODIGE trial in pancreatic cancer.
Susanna Ulahannan, MD, assistant professor, Section of Hematology/Oncology, associate director, Oklahoma TSET Phase I Program, Stephenson Cancer Center, The University of Oklahoma, discusses the PRODIGE trial in pancreatic cancer.
The phase III GI PRODIGE 24/CCTG PA.6 trial was presented at the 2018 ASCO Annual Meeting and examined the use of adjuvant mFOLFIRINOX versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma. The trial was conducted in France and Canada.
The importance of a study like this cannot be understated, as the overall survival (OS) in pancreatic cancer, even resectable pancreatic cancer, is poor, says Ulahannan. OS has typically hovered around 24 months to 28 months with the previous standard of care of gemcitabine and capecitabine.
The modified FOLFIRINOX regimen had an OS of 54.5 months, says Ulahannan, representing a 36% reduction in the risk of death (HR, 0.64; 95% CI, 0.48-0.86; P = .003). The median disease-free survival was 8.8 months longer with mFOLFIRINOX than with gemcitabine.
